199 related articles for article (PubMed ID: 28905539)
21. Complement Inhibitors for the Treatment of Geographic Atrophy.
Amin KV; Hariprasad SM; Danzig CJ
Ophthalmic Surg Lasers Imaging Retina; 2023 Feb; 54(2):66-70. PubMed ID: 36780634
[No Abstract] [Full Text] [Related]
22. Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents.
Gemenetzi M; Lotery AJ; Patel PJ
Eye (Lond); 2017 Jan; 31(1):1-9. PubMed ID: 27716750
[TBL] [Abstract][Full Text] [Related]
23. Complement inhibitors for the treatment of geographic atrophy.
Chew EY
Lancet; 2023 Oct; 402(10411):1396-1398. PubMed ID: 37865456
[No Abstract] [Full Text] [Related]
24. Future perspectives for treating patients with geographic atrophy.
Loewenstein A; Trivizki O
Graefes Arch Clin Exp Ophthalmol; 2023 Jun; 261(6):1525-1531. PubMed ID: 36520185
[TBL] [Abstract][Full Text] [Related]
25. The complement system: a novel therapeutic target for age-related macular degeneration.
Shughoury A; Sevgi DD; Ciulla TA
Expert Opin Pharmacother; 2023; 24(17):1887-1899. PubMed ID: 37691588
[TBL] [Abstract][Full Text] [Related]
26. BETA-PERIPAPILLARY ATROPHY AND GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS.
Kolomeyer AM; Smith E; Daniel E; Ying GS; Pan W; Pistilli M; Grunwald J; Maguire MG; Kim BJ;
Retina; 2021 Jan; 41(1):125-134. PubMed ID: 32383840
[TBL] [Abstract][Full Text] [Related]
27. Progression of Geographic Atrophy with Subsequent Exudative Neovascular Disease in Age-Related Macular Degeneration: AREDS2 Report 24.
Hwang CK; Agrón E; Domalpally A; Cukras CA; Wong WT; Chew EY; Keenan TDL;
Ophthalmol Retina; 2021 Feb; 5(2):108-117. PubMed ID: 33075546
[TBL] [Abstract][Full Text] [Related]
28. Treatment of geographic atrophy: an update on data related to pegcetacoplan.
Patel SB; Heier JS; Chaudhary V; Wykoff CC
Curr Opin Ophthalmol; 2024 Jan; 35(1):64-72. PubMed ID: 37815317
[TBL] [Abstract][Full Text] [Related]
29. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration.
Yaspan BL; Williams DF; Holz FG; Regillo CD; Li Z; Dressen A; van Lookeren Campagne M; Le KN; Graham RR; Beres T; Bhangale TR; Honigberg LA; Smith A; Henry EC; Ho C; Strauss EC;
Sci Transl Med; 2017 Jun; 9(395):. PubMed ID: 28637922
[TBL] [Abstract][Full Text] [Related]
30. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.
Evans JR; Lawrenson JG
Cochrane Database Syst Rev; 2023 Sep; 9(9):CD000254. PubMed ID: 37702300
[TBL] [Abstract][Full Text] [Related]
31. Investigational Agents in Development for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Yu HJ; Wykoff CC
BioDrugs; 2021 May; 35(3):303-323. PubMed ID: 33893984
[TBL] [Abstract][Full Text] [Related]
32. Drug Approval for the Treatment of Geographic Atrophy: How We Got Here and Where We Need to Go.
Csaky KG; Miller JML; Martin DF; Johnson MW
Am J Ophthalmol; 2024 Jul; 263():231-239. PubMed ID: 38387826
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic Options Under Development for Nonneovascular Age-Related Macular Degeneration and Geographic Atrophy.
Kim JB; Lad EM
Drugs Aging; 2021 Jan; 38(1):17-27. PubMed ID: 33355716
[TBL] [Abstract][Full Text] [Related]
34. The case for complement and inflammation in AMD: open questions.
Karagianni N; Adamis AP
Adv Exp Med Biol; 2010; 703():1-7. PubMed ID: 20711703
[TBL] [Abstract][Full Text] [Related]
35. Latest Developments in the Management of AMD.
Chang A; Schlottmann PG; Chan RVP
Asia Pac J Ophthalmol (Phila); 2017; 6(6):477-478. PubMed ID: 29204992
[No Abstract] [Full Text] [Related]
36. Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy.
Wykoff CC; Rosenfeld PJ; Waheed NK; Singh RP; Ronca N; Slakter JS; Staurenghi G; Monés J; Baumal CR; Saroj N; Metlapally R; Ribeiro R
Ophthalmology; 2021 Sep; 128(9):1325-1336. PubMed ID: 33711380
[TBL] [Abstract][Full Text] [Related]
37. The Role of Inflammation in Age-Related Macular Degeneration-Therapeutic Landscapes in Geographic Atrophy.
Borchert GA; Shamsnajafabadi H; Hu ML; De Silva SR; Downes SM; MacLaren RE; Xue K; Cehajic-Kapetanovic J
Cells; 2023 Aug; 12(16):. PubMed ID: 37626902
[TBL] [Abstract][Full Text] [Related]
38. Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16.
Keenan TD; Agrón E; Domalpally A; Clemons TE; van Asten F; Wong WT; Danis RG; Sadda S; Rosenfeld PJ; Klein ML; Ratnapriya R; Swaroop A; Ferris FL; Chew EY;
Ophthalmology; 2018 Dec; 125(12):1913-1928. PubMed ID: 30060980
[TBL] [Abstract][Full Text] [Related]
39. Central geographic atrophy vs. neovascular age-related macular degeneration: differences in longitudinal vision-related quality of life.
Ahluwalia A; Shen LL; Del Priore LV
Graefes Arch Clin Exp Ophthalmol; 2021 Feb; 259(2):307-316. PubMed ID: 32813108
[TBL] [Abstract][Full Text] [Related]
40. SYSTEMIC MEDICATION USE AND THE INCIDENCE AND GROWTH OF GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS.
Song D; Hua P; VanderBeek BL; Dunaief JL; Grunwald JE; Daniel E; Maguire MG; Martin DF; Ying GS;
Retina; 2021 Jul; 41(7):1455-1462. PubMed ID: 33332813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
